{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:59:14Z","timestamp":1790787554363,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470921"],"award-info":[{"award-number":["32470921"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31970845"],"award-info":[{"award-number":["31970845"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82525029"],"award-info":[{"award-number":["82525029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971871"],"award-info":[{"award-number":["81971871"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130053"],"award-info":[{"award-number":["82130053"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["D20036"],"award-info":[{"award-number":["D20036"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jare.2026.01.067","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T15:35:19Z","timestamp":1769355319000},"page":"561-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel extracellular vesicle-engineered immunotherapy drug for Her2+ breast cancer"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2115-1647","authenticated-orcid":false,"given":"Xinliang","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianchang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gensheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2026.01.067_b0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchio","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jare.2026.01.067_b0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.jare.2026.01.067_b0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jare.2026.01.067_b0020","first-page":"451","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.jare.2026.01.067_b0025","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jare.2026.01.067_b0030","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.01.067_b0035","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","article-title":"A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy","volume":"35","author":"Tian","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jare.2026.01.067_b0040","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/s41467-018-04791-8","article-title":"Efficient RNA drug delivery using red blood cell extracellular vesicles","volume":"9","author":"Usman","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.01.067_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12030","article-title":"Extracellular vesicles: natural liver-accumulating drug delivery vehicles for the treatment of liver diseases","volume":"10","author":"Zhang","year":"2020","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.jare.2026.01.067_b0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nano.2017.09.011","article-title":"Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations","volume":"14","author":"Kim","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jare.2026.01.067_b0055","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jare.2026.01.067_b0060","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1038\/s41467-022-31250-2","article-title":"Breast cancer cell-derived extracellular vesicles promote CD8(+) T cell exhaustion via TGF-beta type II receptor signaling","volume":"13","author":"Xie","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.01.067_b0065","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.2147\/IJN.S313912","article-title":"Tumor-derived extracellular vesicles: their role in immune cells and immunotherapy","volume":"16","author":"Li","year":"2021","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.jare.2026.01.067_b0070","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12426","article-title":"Proton pump inhibitors enhance macropinocytosis-mediated extracellular vesicle endocytosis by inducing membrane v-ATPase assembly","volume":"13","author":"Lu","year":"2024","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.jare.2026.01.067_b0075","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2404778121","article-title":"Metformin synergizes with PD-1 blockade to promote normalization of tumor vessels via CD8T cells and IFNgamma","volume":"121","author":"Tokumasu","year":"2024","journal-title":"PNAS"},{"key":"10.1016\/j.jare.2026.01.067_b0080","doi-asserted-by":"crossref","unstructured":"Liu X, et al. Kynurenine-AhR reduces T-cell infiltration and induces a delayed T-cell immune response by suppressing the STAT1-CXCL9\/CXCL10 axis in tuberculosis. Cell Mol Immunol (2024)","DOI":"10.1038\/s41423-024-01230-1"},{"key":"10.1016\/j.jare.2026.01.067_b0085","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-022-02523-x","article-title":"B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met\/AKT\/mTOR\/IRF-1 axis in neuroblastoma","volume":"41","author":"Sha","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jare.2026.01.067_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1258156","article-title":"Humanized single-domain antibody targeting HER2 enhances function of chimeric antigen receptor T cells","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2026.01.067_b0095","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/s41419-021-04100-0","article-title":"HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jare.2026.01.067_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105041","article-title":"Tumor-derived extracellular vesicles: regulators of tumor microenvironment and the enlightenment in tumor therapy","volume":"159","author":"Chen","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jare.2026.01.067_b0105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pharmthera.2005.05.002","article-title":"FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors","volume":"108","author":"Chiba","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jare.2026.01.067_b0110","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.apsb.2020.12.021","article-title":"Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo","volume":"11","author":"Wu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.jare.2026.01.067_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.811485","article-title":"Vascular Microenvironment, Tumor Immunity and Immunotherapy","volume":"12","author":"Lamplugh","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2026.01.067_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.702726","article-title":"Regulatory T cells: barriers of immune infiltration into the tumor microenvironment","volume":"12","author":"Scott","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2026.01.067_b0125","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2026.01.067_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","article-title":"Immune suppressive mechanisms in the tumor microenvironment","volume":"39","author":"Munn","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jare.2026.01.067_b0135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-023-01898-5","article-title":"Extracellular vesicles remodel tumor environment for cancer immunotherapy","volume":"22","author":"Yue","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2026.01.067_b0140","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI81136","article-title":"Exosomes and tumor-mediated immune suppression","volume":"126","author":"Whiteside","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jare.2026.01.067_b0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.canlet.2021.10.023","article-title":"Tumor perivascular cell-derived extracellular vesicles promote angiogenesis via the Gas6\/Axl pathway","volume":"524","author":"Huang","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jare.2026.01.067_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.790489","article-title":"Tumor-derived extracellular vesicles induce abnormal angiogenesis via TRPV4 downregulation and subsequent activation of YAP and VEGFR2","volume":"9","author":"Guarino","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.jare.2026.01.067_b0155","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","author":"Trastuzumab for early-stage","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jare.2026.01.067_b0160","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1056\/NEJMct1114348","article-title":"Anti-CD20 antibody therapy for B-cell lymphomas","volume":"366","author":"Maloney","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.01.067_b0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12987-022-00359-3","article-title":"Extracellular vesicles through the blood-brain barrier: a review","volume":"19","author":"Ramos-Zaldivar","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.jare.2026.01.067_b0170","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43018-020-0082-y","article-title":"Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4(+) and PDPN(+) CAFs to clinical outcome","volume":"1","author":"Friedman","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jare.2026.01.067_b0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13075-022-02902-x","article-title":"Identification of HBEGF+ fibroblasts in the remission of rheumatoid arthritis by integrating single-cell RNA sequencing datasets and bulk RNA sequencing datasets","volume":"24","author":"Chen","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jare.2026.01.067_b0180","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat Methods"},{"key":"10.1016\/j.jare.2026.01.067_b0185","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41591-020-0944-y","article-title":"A single-cell atlas of the peripheral immune response in patients with severe COVID-19","volume":"26","author":"Wilk","year":"2020","journal-title":"Nat Med"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226000925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226000925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:57:39Z","timestamp":1790783859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123226000925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"alternative-id":["S2090123226000925"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2026.01.067","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel extracellular vesicle-engineered immunotherapy drug for Her2+ breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2026.01.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}